BioMaxima S.A. (WSE:BMX)
12.85
+0.05 (0.39%)
At close: Feb 5, 2026
BioMaxima Revenue
BioMaxima had revenue of 15.91M PLN in the quarter ending September 30, 2025, with 27.67% growth. This brings the company's revenue in the last twelve months to 59.11M, up 17.50% year-over-year. In the year 2024, BioMaxima had annual revenue of 52.85M with 12.96% growth.
Revenue (ttm)
59.11M
Revenue Growth
+17.50%
P/S Ratio
0.91
Revenue / Employee
437.87K
Employees
135
Market Cap
53.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52.85M | 6.07M | 12.96% |
| Dec 31, 2023 | 46.79M | -97.08M | -67.48% |
| Dec 31, 2022 | 143.87M | 64.78M | 81.91% |
| Dec 31, 2021 | 79.09M | 17.81M | 29.06% |
| Dec 31, 2020 | 61.28M | 30.67M | 100.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 13.34B |
| Diagnostyka | 2.30B |
| Synektik Spólka Akcyjna | 681.60M |
| Voxel | 568.83M |
| Sygnis | 15.41M |
| Read-Gene | 15.19M |
| Urteste | 1.80M |
| Pharmena | 1.27M |